Tech Company Financing Transactions
Atea Pharmaceuticals Funding Round
Atea Pharmaceuticals, operating out of Boston, raised $215 million in investment from Bain Capital Life Sciences, Perceptive Advisors and RA Capital.
Transaction Overview
Company Name
Announced On
5/21/2020
Transaction Type
Venture Equity
Amount
$215,000,000
Round
Series D
Proceeds Purpose
The series D will enable Atea to test that hypothesis in a phase 2 trial that is scheduled to start this month and has an estimated primary completion date in July.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
125 Summer St.
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Not Recorded
Overview
Discovering and rapidly advancing transformative antiviral therapies. Atea (Nasdaq: AVIR) is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Sommadossi
Chief Financial Officer
Daniel Geffken
Chief Medical Officer
Nathaniel Brown
Executive Vice President
Steven Good
Executive Vice President
Adel Mousa
Executive Vice President
Xiao-Jian Zhou
VP - Bus. Development
John Vavricka
VP - Finance
Wayne Foster
VP - General Counsel
Andrea Corcoran
VP - Operations
Keith Pietropaolo
Browse more venture capital transactions:
Prev: 5/21/2020: Coalition venture capital transaction
Next: 5/21/2020: Aqua Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs